Sunshine Biopharma (NASDAQ:SBFM) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Sunshine Biopharma (NASDAQ:SBFM) to a hold rating in a research note published on Saturday morning.

A number of other analysts also recently issued reports on SBFM. Weiss Ratings downgraded Sunshine Biopharma from a “sell (e+)” rating to a “sell (e)” rating in a research note on Tuesday, August 11th. Zacks Research upgraded Sunshine Biopharma to a “hold” rating in a research report on Wednesday, May 27th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $70.00.

Sunshine Biopharma Trading Down 2.6%

Shares of SBFM stock opened at $1.12 on Friday. Sunshine Biopharma has a 12-month low of $1.03 and a 12-month high of $24.30. The stock’s 50-day moving average price is $1.79 and its 200-day moving average price is $6.78. The stock has a market capitalization of $560,000.00, a price-to-earnings ratio of -0.11 and a beta of 1.17.

Sunshine Biopharma (NASDAQ:SBFM) last posted its earnings results on Thursday, August 13th. The company reported ($1.15) EPS for the quarter, topping analysts’ consensus estimates of ($1.20) by $0.05. Sunshine Biopharma had a negative return on equity of 26.36% and a negative net margin of 17.94%.The company had revenue of $9.26 million for the quarter, compared to the consensus estimate of $8.70 million. As a group, research analysts predict that Sunshine Biopharma will post -6.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC increased its stake in Sunshine Biopharma by 23.1% during the third quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock worth $116,000 after acquiring an additional 14,656 shares during the last quarter. Two Sigma Investments LP bought a new stake in shares of Sunshine Biopharma in the 3rd quarter valued at approximately $32,000. Finally, Virtu Financial LLC bought a new stake in shares of Sunshine Biopharma in the 4th quarter valued at approximately $29,000. Hedge funds and other institutional investors own 41.98% of the company’s stock.

About Sunshine Biopharma

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.